Letters, Testimony & Comments

BIO submits letters, testimony, and comments to government and regulatory bodies throughout the United States and around the world.

Featured Letters, Testimony, & Comments
BIO Joins Coalition Letter to Biden…
Dear Secretary Buttigieg, National Climate Advisor McCarthy, and Director Deese: The undersigned organizations, representing aviation industry stakeholders including passenger and cargo carriers, business and general aviation, aircraft and engine…
BIO Comments on FDA’s Draft Guidance on Human…
On Tuesday, April 6th, BIO submitted comments on the U.S. Food and Drug Administration (FDA)’s January 2021 draft industry guidance on “Human Gene Therapy for Neurodegenerative Diseases.” In its comments, BIO stated that while the guidance covers…
BIO Comments on FDA’s Public Meeting Announcement…
On Friday, March 26th, BIO submitted comments on the U.S. Food and Drug Administration (FDA)’s public meeting announcement titled, “Best Practices for Development and Application of Disease Progression Models.” BIO appreciates that FDA is seeking…
All Letters, Testimony & Comments
  • Show All
Search
April 9, 2021
The Biotechnology Innovation Organization (BIO) submitted the below comments to the National Institute of Standards and Technology on proposed revisions to regulations that would further the Return on Investment (ROI) Initiative for Unleashing…
April 6, 2021
On Tuesday, April 6th, BIO submitted comments on the U.S. Food and Drug Administration (FDA)’s January 2021 draft industry guidance on “Human Gene Therapy for Neurodegenerative Diseases.” In its comments, BIO stated that while the guidance covers…
April 2, 2021
Dear Secretary Buttigieg, National Climate Advisor McCarthy, and Director Deese: The undersigned organizations, representing aviation industry stakeholders including passenger and cargo carriers, business and general aviation, aircraft and engine…
March 26, 2021
On Friday, March 26th, BIO submitted comments on the U.S. Food and Drug Administration (FDA)’s public meeting announcement titled, “Best Practices for Development and Application of Disease Progression Models.” BIO appreciates that FDA is seeking…
March 26, 2021
The Biotechnology Innovation Organization is delighted to support the Inventor Diversity for Economic Advancement Act of 2021 and urge swift enactment of this important measure.
March 24, 2021
The Biotechnology Innovation Organization is pleased to submit a statement for the record to the United States House of Representatives Committee on Science and Technology and Space and Aeronautics Subcommittee hearing entitled, "Examining R&D…
March 22, 2021
I write today on behalf of the Biotechnology Industry Organization (BIO) – the world’s largest biotechnology trade group – to urge you to put Senate Bill 11 – the New Mexico Clean Fuel Standard Act – on the agenda for the March 31 special session of…
March 18, 2021
The Biotechnology Innovation Organization (BIO) is pleased to submit a statement for the record to the United States House of Representatives Committee on Energy and Commerce Subcommittee on Environment and Climate Change hearing entitled, "The…
March 17, 2021
The Biotechnology Innovation Organization (BIO) welcomes the United Kingdom’s (UK) consultation on the application of genome editing in the breeding of plants and animals.  The UK has the unique opportunity to be the first country within Europe…
March 11, 2021
The Biotechnology Innovation Organization (BIO) is pleased to submit a statement for the record to the United States Senate Committee on Agriculture, Nutrition, and Forestry hearing entitled, “Farmers and Foresters: Opportunities to Lead in Tackling…